161 related articles for article (PubMed ID: 24288674)
1. Gsk-3β inhibitors mimic the cardioprotection mediated by ischemic pre- and postconditioning in hypertensive rats.
González Arbeláez LF; Pérez Núñez IA; Mosca SM
Biomed Res Int; 2013; 2013():317456. PubMed ID: 24288674
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine-A mimicked the ischemic pre- and postconditioning-mediated cardioprotection in hypertensive rats: Role of PKCε.
González Arbeláez LF; Ciocci Pardo A; Fantinelli JC; Mosca SM
Exp Mol Pathol; 2016 Apr; 100(2):266-75. PubMed ID: 26844384
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied hearts.
Barillas R; Friehs I; Cao-Danh H; Martinez JF; del Nido PJ
Ann Thorac Surg; 2007 Jul; 84(1):126-33. PubMed ID: 17588398
[TBL] [Abstract][Full Text] [Related]
4. Hypercholesterolemia abrogates the cardioprotection of ischemic postconditioning in isolated rat heart: roles of glycogen synthase kinase-3β and the mitochondrial permeability transition pore.
Wu N; Zhang X; Guan Y; Shu W; Jia P; Jia D
Cell Biochem Biophys; 2014 May; 69(1):123-30. PubMed ID: 24213808
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of GSK-3β produces late phase of cardioprotection in hyperlipidemic rat: possible involvement of HSP 72.
Yadav HN; Singh M; Sharma PL
Mol Cell Biochem; 2012 Oct; 369(1-2):227-33. PubMed ID: 22810500
[TBL] [Abstract][Full Text] [Related]
6. Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK-3beta: interaction with the MPT pore.
Mozaffari MS; Schaffer SW
Am J Hypertens; 2008 May; 21(5):570-5. PubMed ID: 18437149
[TBL] [Abstract][Full Text] [Related]
7. Morphine preconditioning confers cardioprotection in doxorubicin-induced failing rat hearts via ERK/GSK-3β pathway independent of PI3K/Akt.
He SF; Jin SY; Wu H; Wang B; Wu YX; Zhang SJ; Irwin MG; Wong TM; Zhang Y
Toxicol Appl Pharmacol; 2015 Nov; 288(3):349-58. PubMed ID: 26296503
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of ischemia-reperfusion injury by sevoflurane postconditioning involves protein kinase B and glycogen synthase kinase 3 beta activation in isolated rat hearts.
Fang NX; Yao YT; Shi CX; Li LH
Mol Biol Rep; 2010 Dec; 37(8):3763-9. PubMed ID: 20217242
[TBL] [Abstract][Full Text] [Related]
9. Indirubin-3'-oxime prevents hepatic I/R damage by inhibiting GSK-3beta and mitochondrial permeability transition.
Varela AT; Simões AM; Teodoro JS; Duarte FV; Gomes AP; Palmeira CM; Rolo AP
Mitochondrion; 2010 Aug; 10(5):456-63. PubMed ID: 20433952
[TBL] [Abstract][Full Text] [Related]
10. Diabetes abolishes the cardioprotection induced by sevoflurane postconditioning in the rat heart in vivo: roles of glycogen synthase kinase-3β and its upstream pathways.
Tai W; Shi E; Yan L; Jiang X; Ma H; Ai C
J Surg Res; 2012 Nov; 178(1):96-104. PubMed ID: 22482760
[TBL] [Abstract][Full Text] [Related]
11. Ischemic postconditioning mediates cardioprotection via PI3K/GSK-3β/β-catenin signaling pathway in ischemic rat myocardium.
Wu QL; Shen T; Shao LL; Ma H; Wang JK
Shock; 2012 Aug; 38(2):165-9. PubMed ID: 22576003
[TBL] [Abstract][Full Text] [Related]
12. Roles of phospho-GSK-3β in myocardial protection afforded by activation of the mitochondrial K ATP channel.
Terashima Y; Sato T; Yano T; Maas O; Itoh T; Miki T; Tanno M; Kuno A; Shimamoto K; Miura T
J Mol Cell Cardiol; 2010 Nov; 49(5):762-70. PubMed ID: 20692265
[TBL] [Abstract][Full Text] [Related]
13. Involvement of GSK-3β in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart.
Yadav HN; Singh M; Sharma PL
Mol Cell Biochem; 2010 Oct; 343(1-2):75-81. PubMed ID: 20512612
[TBL] [Abstract][Full Text] [Related]
14. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways.
Vigneron F; Dos Santos P; Lemoine S; Bonnet M; Tariosse L; Couffinhal T; Duplaà C; Jaspard-Vinassa B
Cardiovasc Res; 2011 Apr; 90(1):49-56. PubMed ID: 21233250
[TBL] [Abstract][Full Text] [Related]
15. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling.
Ghaboura N; Tamareille S; Ducluzeau PH; Grimaud L; Loufrani L; Croué A; Tourmen Y; Henrion D; Furber A; Prunier F
Basic Res Cardiol; 2011 Jan; 106(1):147-62. PubMed ID: 20981553
[TBL] [Abstract][Full Text] [Related]
16. Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3β in Rats.
Qiao S; Mao X; Wang Y; Lei S; Liu Y; Wang T; Wong GT; Cheung CW; Xia Z; Irwin MG
Crit Care Med; 2016 Mar; 44(3):e131-45. PubMed ID: 26468894
[TBL] [Abstract][Full Text] [Related]
17. Sevoflurane confers additive cardioprotection to ethanol preconditioning associated with enhanced phosphorylation of glycogen synthase kinase-3β and inhibition of mitochondrial permeability transition pore opening.
Onishi A; Miyamae M; Inoue H; Kaneda K; Okusa C; Inamura Y; Shiomi M; Koshinuma S; Momota Y; Figueredo VM
J Cardiothorac Vasc Anesth; 2013 Oct; 27(5):916-24. PubMed ID: 23266287
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation.
Das S; Wong R; Rajapakse N; Murphy E; Steenbergen C
Circ Res; 2008 Oct; 103(9):983-91. PubMed ID: 18802025
[TBL] [Abstract][Full Text] [Related]
19. Local delivery of PKCepsilon-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation.
Korzick DH; Kostyak JC; Hunter JC; Saupe KW
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2056-63. PubMed ID: 17675573
[TBL] [Abstract][Full Text] [Related]
20. Lithium exacerbates hepatic ischemia/reperfusion injury by inhibiting GSK-3β/NF-κB-mediated protective signaling in mice.
Xia Y; Rao J; Yao A; Zhang F; Li G; Wang X; Lu L
Eur J Pharmacol; 2012 Dec; 697(1-3):117-25. PubMed ID: 23051669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
